TUB Stock Overview
Operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €130.60 |
| 52 Week High | €149.00 |
| 52 Week Low | €64.80 |
| Beta | 0.40 |
| 11 Month Change | -8.29% |
| 3 Month Change | 11.24% |
| 1 Year Change | 98.48% |
| 33 Year Change | 46.91% |
| 5 Year Change | 105.35% |
| Change since IPO | 2,231.31% |
Recent News & Updates
Shareholder Returns
| TUB | BE Pharmaceuticals | BE Market | |
|---|---|---|---|
| 7D | -9.6% | -3.0% | -1.6% |
| 1Y | 98.5% | 4.3% | 2.0% |
Return vs Industry: TUB exceeded the Belgian Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: TUB exceeded the Belgian Market which returned 2.7% over the past year.
Price Volatility
| TUB volatility | |
|---|---|
| TUB Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in BE Market | 6.3% |
| 10% least volatile stocks in BE Market | 2.1% |
Stable Share Price: TUB has not had significant price volatility in the past 3 months compared to the Belgian market.
Volatility Over Time: TUB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
| TUB fundamental statistics | |
|---|---|
| Market cap | €5.81b |
| Earnings (TTM) | €90.02m |
| Revenue (TTM) | n/a |
64.6x
P/E Ratio0.0x
P/S RatioIs TUB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TUB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €2.00m |
| Gross Profit | -€2.00m |
| Other Expenses | -€92.02m |
| Earnings | €90.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Aug 02, 2025
| Earnings per share (EPS) | 2.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 1.6% |
How did TUB perform over the long term?
See historical performance and comparison